[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hassan et al., 2021 - Google Patents

Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors

Hassan et al., 2021

Document ID
6260177311045457372
Author
Hassan G
Georgey H
Mohammed E
George R
Mahmoud W
Omar F
Publication year
Publication venue
European Journal of Medicinal Chemistry

External Links

Snippet

Novel series of diphenyl-1H-pyrazoles (4a-g) and pyrazolo [3, 4-b] pyridines (5a-g and 7a-i) were synthesized and evaluated for their antiproliferative activity against breast cancer cell line (MCF7) and Hepatocellular carcinoma cell line (HepG2). The highest MCF7 growth …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Similar Documents

Publication Publication Date Title
Hassan et al. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors
Batran et al. New coumarin derivatives as anti‐breast and anti‐cervical cancer agents targeting VEGFR‐2 and p38α MAPK
Latif et al. 3-Substituted-4-hydroxycoumarin as a new scaffold with potent CDK inhibition and promising anticancer effect: Synthesis, molecular modeling and QSAR studies
Almehmadi et al. Synthesis of a new series of pyrazolo [1, 5-a] pyrimidines as CDK2 inhibitors and anti-leukemia
Song et al. Synthesis and biological evaluation of novel pyrazoline derivatives containing indole skeleton as anti-cancer agents targeting topoisomerase II
Santosh et al. Design, synthesis, and pharmacology of some oxadiazole and hydroxypyrazoline hybrids bearing thiazoyl scaffold: antiproliferative activity, molecular docking and DNA binding studies
Lu et al. Design, combinatorial synthesis and biological evaluations of novel 3-amino-1′-((1-aryl-1H-1, 2, 3-triazol-5-yl) methyl)-2′-oxospiro [benzo [a] pyrano [2, 3-c] phenazine-1, 3′-indoline]-2-carbonitrile antitumor hybrid molecules
Azmy et al. Development of pyrolo [2, 3-c] pyrazole, pyrolo [2, 3-d] pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations
Briguglio et al. Triazolopyridinyl-acrylonitrile derivatives as antimicrotubule agents: Synthesis, in vitro and in silico characterization of antiproliferative activity, inhibition of tubulin polymerization and binding thermodynamics
Rostom et al. Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies
Bhambra et al. Novel fluorinated benzimidazole-based scaffolds and their anticancer activity in vitro
Zhang et al. Ligand-and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia
Matthews et al. Identification of inhibitors of checkpoint kinase 1 through template screening
Boček et al. Imidazo [4, 5-b] pyridine derived tubulin polymerization inhibitors: Design, synthesis, biological activity in vitro and computational analysis
Nossier et al. Modified pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation
Sun et al. Design, synthesis, and biological evaluation of novel pyrazolo [3, 4-d] pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer
Roby et al. Synthesis of new set of imidazo [1, 2-a] pyridine-schiff bases derivatives as potential antimicrobial agents: Experimental and theoretical approaches
Alotaibi et al. Novel pyrrolo [2, 3-d] pyrimidine derivatives as multi-kinase inhibitors with VEGFR-2 selectivity
Theodore et al. Design, synthesis, anticancer activity and molecular docking of novel 1H-benzo [d] imidazole derivatives as potential EGFR inhibitors
Song et al. Application of deep generative model for design of Pyrrolo [2, 3-d] pyrimidine derivatives as new selective TANK binding kinase 1 (TBK1) inhibitors
Sanad et al. New thieno [2, 3-b] pyridine-fused pyrimidin-4 (3H)-ones as potential thymidylate synthase inhibitors: Synthesis, SAR, in vitro and in silico study
Hassan et al. Design and synthesis of new series of chiral pyrimidine and purine analogs as COX-2 inhibitors: Anticancer screening, molecular modeling, and in silico studies
Abd El-Mawgoud et al. Design, synthesis and cytotoxic evaluation of new thieno [2, 3-d] pyrimidine analogues as VEGFR-2/AKT dual inhibitors, apoptosis and autophagy inducers
Abouelenein et al. Synthesis, molecular modeling Insights, and anticancer assessment of novel polyfunctionalized Pyridine congeners
Eissa et al. Identification of new theobromine-based derivatives as potent VEGFR-2 inhibitors: design, semi-synthesis, biological evaluation, and in silico studies